Ever since the U.S. Supreme Court issued its opinions in Mayo Collaborative Services v. Prometheus Laboratories, Inc.1, Association for Molecular Pathology v. Myriad Genetics, Inc.2, and Alice Corporation Pty. Ltd. v. CLS Bank International3, the U.S. Patent and Trademark Office (USPTO), the Court of Appeals for the Federal Circuit, and the public at large have grappled with understanding the metes and bounds of patent subject matter eligibility. The USPTO has done its best to issue guidelines and illustrative examples for patent examiners and patent applicants to follow in order to obtain the broadest patent protection consistent with Supreme Court precedent.
It is interesting that despite the admonitions explicitly stated in these cases to not overly broadly apply the holdings of those cases4,5,6,7, these highly fact-specific holdings have indeed been broadly applied across technologies, essentially creating chaos in the U.S. patent system.
The effects of this overly broad application are far-reaching, including discouraging foreign entities from pursuing patent protection in the U.S., and discouraging the investment in research by U.S. entities that would no longer be entitled to the reward of a limited period of protection for potentially life-enhancing, if not life-saving inventions. The stifling of American innovation seems particularly contrary to the goals of the current administration.
Moreover, the overly broad application of these cases could also be considered a violation of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs), which defines the minimum standards for intellectual property rights in over 170 countries. TRIPs requires that:
…patents shall be available for any inventions, whether products or processes, in all fields of technology, provided that they are new, involve an inventive step and are capable of industrial application... patents shall be available and patent rights enjoyable without discrimination as to the place of invention, the field of technology and whether products are imported or locally produced.
While the Federal Circuit has incorporated into recent decisions a plea to the U.S. Congress to legislatively deal with the chaos the Supreme Court cases have created8,9, it has in recent cases declined to review the eligibility of claims in accordance with the USPTO’s guidelines and examples10. In Cleveland Clinic Foundation v. True Health Diagnostics, LLC (Cleveland Clinic II)11, the Federal Circuit declined to consider a claim’s similarity to Example 29 of the USPTO’s eligibility guidance, but rather considered the claim to be “strikingly similar” to the claim found by the Federal Circuit to be ineligible in Ariosa Diagnostics, Inc. v. Sequenom, Inc.12
In similar fashion, in ChargePoint, Inc. v. SemaConnect, Inc.13, the Federal Circuit found that an apparatus incorporating a control device, a transceiver and a controller was merely an abstract idea because it was based upon “communicating requests to a remote server and receiving communications from that server, i.e., communication over a network.” Indeed, the Federal Circuit appeared to ignore the fact that the claim was directed to an apparatus (i.e., a “new and useful machine” under 35 U.S.C. § 101), and did not “evaluate whether the claim as a whole integrates the recited judicial exception into a practical application of the exception.” It has been suggested that:
Based on the Chargepoint decision, inventors, business leaders and attorneys cannot, or should not, rely on the USPTO’s new 101 guidance. Unfortunately, with this decision, the guidance is now worthless.14
There are members of the U.S. Congress who appear to be cognizant of the need to deal with the uncertainties relating to 35 U.S.C. § 101 in view of these Supreme Court cases. During the 115th Congress, 2d Session, a bill (HR 6264) was introduced by Representatives Thomas Massie (R-KY, 4th dist.) and Marcy Kaptur (D-OH, 9th dist.), that proposed numerous changes to effectively reverse much of the Obama-era America Invents Act (“AIA”), and sought to amend 35 U.S.C. § 101, in similar fashion to proposals by Intellectual Property Owners (IPO), American Intellectual Property Law Association (AIPLA) and New York Intellectual Property Law Association (NYIPLA). These proposals sought to: (1) define specific exceptions to patent eligibility “if and only if the claimed invention as a whole (i) exists in nature independently of and prior to any human activity or (ii) is performed solely in the human mind”; and (2) make clear that the eligibility of a claimed invention “shall be determined without regard to: (1) the requirements or conditions of sections 102, 103, and 112 of [35 U.S.C.]…"15
On April 17, 2019, Senator Thom Tillis (R-NC), Chair of the Senate Judiciary Subcommittee on Intellectual Property, Senator Chris Coons (D-DE), Ranking Member, Representative Doug Collins (R-GA-9), Ranking Member of the House Judiciary Committee, and Representatives Hank Johnson (D-GA-4), and Steve Stivers (R-OH-15), released a "bipartisan, bicameral framework on Section 101 patent reform."16 Senator Tillis noted:
Senator Coons and I requested to reinstate the Senate Judiciary Subcommittee on IP because we saw a need to reform our nation’s complicated patent process, starting with section 101.
Senator Coons added:
Today, U.S. patent law discourages innovation in some of the most critical areas of technology, including artificial intelligence, medical diagnostics, and personalized medicine.
And Representative Collins concluded:
Upgrading the patent eligibility test is critical if we want American innovation to continue to lead worldwide.
The framework proposes:
DRAFT OUTLINE OF SECTION 101 REFORM
- Keep existing statutory categories of process, machine, manufacture, or composition of matter, or any useful improvement thereof.
- Eliminate, within the eligibility requirement, that any invention or discovery be both “new and useful.” Instead, simply require that the invention meet existing statutory utility requirements.
- Define, in a closed list, exclusive categories of statutory subject matter which alone should not be eligible for patent protection. The sole list of exclusions might include the following categories, for example:
- Fundamental scientific principles;
- Products that exist solely and exclusively in nature;
- Pure mathematical formulas;
- Economic or commercial principles;
- Mental activities.
- Create a “practical application” test to ensure that the statutorily ineligible subject matter is construed narrowly.
- Ensure that simply reciting generic technical language or generic functional language does not salvage an otherwise ineligible claim.
- Statutorily abrogate judicially created exceptions to patent eligible subject matter in favor of exclusive statutory categories of ineligible subject matter.
- Make clear that eligibility is determined by considering each and every element of the claim as a whole and without regard to considerations properly addressed by 102, 103 and 112.
The Senators and Representatives encourage stakeholders to email IntellectualProperty@tillis.senate.gov with comments.
In view of these recent developments, practitioners should be aware that claims found to be subject-matter eligible in the USPTO in accordance with the USPTO’s guidance may not withstand challenge at the Federal Circuit. While the introduction of changes to 35 U.S.C. § 101 could, on the one hand, lead to greater clarity, providing what appear to be “bright line” exclusions in the statute could provide statutory authority for continuing the overly broad application of Supreme Court precedent.